Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
49.56
+2.41 (+5.10%)
Streaming Delayed Price
Updated: 10:30 AM EST, Nov 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
301,998
Open
47.22
Bid (Size)
49.51 (1)
Ask (Size)
49.62 (4)
Prev. Close
47.16
Today's Range
47.16 - 49.62
52wk Range
19.83 - 94.45
Shares Outstanding
116,457,008
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Magnificent 7 Take Center Stage In Hedge Fund Portfolios: Analysts Warn Of Extreme Concentration
November 21, 2023
Hedge fund portfolios are intensifying their focus on technology stocks, with holdings in mega-cap tech reaching record levels.
Via
Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-1.42%
-1.42%
1 Month
+3.45%
+3.45%
3 Month
+21.93%
+21.93%
6 Month
-44.68%
-44.68%
1 Year
-2.12%
-2.12%
More News
Read More
NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc.
November 14, 2023
Via
SBWire
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
November 06, 2023
Via
Benzinga
21 Analysts Have This to Say About Apellis Pharmaceuticals
November 02, 2023
Via
Benzinga
Analyst Ratings for Apellis Pharmaceuticals
October 06, 2023
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
November 04, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 02, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Why Apellis Pharmaceuticals Stock Popped Today
October 05, 2023
Via
Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
November 01, 2023
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
October 31, 2023
Via
Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Via
Investor's Business Daily
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
October 25, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
October 24, 2023
Via
Investor's Business Daily
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
October 20, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
October 18, 2023
Via
Benzinga
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
October 17, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks Mixed Amid Earnings, Consumer Sentiment Data
October 13, 2023
Via
Talk Markets
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday
October 13, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
October 06, 2023
Via
Benzinga
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
October 06, 2023
Via
Benzinga
Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday
October 06, 2023
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.